Whalesbook
Arre bhaiyo aur behno, Serum Institute of India ke founder, Cyrus Poonawalla ko haal hi mein ek Lifetime Achievement Award mila hai, jo India ki vaccine manufacturing power ko dikhata hai. SII duniya ka sabse bada vaccine producer hai, jinhone lakhon logon ki jaan bachai hai aur vaccines ko affordable banaya hai, khas kar COVID-19 ke time pe. Lekin, Poonawalla ne ek important baat pakdi hai – future mein global leader bane rehne ke liye sirf manufacturing capacity aur low cost pe depend karna kaafi nahi hai. Unka kehna hai ki India ko ab R&D (Research and Development) mein zyada paisa lagana hoga, regulatory approvals ko quick karna hoga aur supply chains ko aur mazboot banana hoga. Innovation hi aage badhne ka raasta hai, sirf bana kar nahi chalega!
Dekho, India ki vaccine market toh waise bhi mast grow kar rahi hai. Estimates hain ki yeh 2026 tak $71.9 billion aur 2036 tak $132.2 billion tak pahunch jayegi. Iska reason hai desh aur duniya mein vaccination programs ka badhna. Aajkal new tech jaise mRNA aur nucleic acid technologies aa rahi hain, jo bohot fast development allow karti hain. Yahan par hi toh asli challenge hai! Pfizer, Moderna aur GSK jaise global players ismein lead kar rahe hain. Agar India ne R&D pe focus nahi kiya, toh hum peeche reh jayenge aur next-gen vaccines mein bas follower ban kar reh jayenge.
Good news yeh hai ki government ne regulatory process ko improve kiya hai. Ab drugs develop karne aur clinical trials ke approvals ka time 50% se zyada kam ho gaya hai. Marketing approvals 150 din se bhi kam mein mil rahe hain. Yeh Sun Pharmaceutical Industries, Cipla, aur Dr. Reddy's Laboratories jaise publicly traded Indian pharma companies ke liye bohot faydemand hai, kyunki unka time-to-market kam hoga aur woh zyada competitive banenge.
Lekin risk toh hai hi. Agar hum past success par hi baithe rahe aur R&D mein innovation ki speed match nahi ki, especially mRNA technology mein, toh hum global race mein piche khinch sakte hain. Naye diseases ke liye jaldi vaccine banana mushkil ho jayega. Bharat Biotech jaise domestic players bhi innovative vaccines bana rahe hain, toh internal competition bhi hai. Aur global supply chain mein jo fluctuations aate rehte hain, unko bhi handle karna hai.
Future ki baat karein toh, Indian pharmaceutical sector bohot achha perform kar raha hai. 2031 tak revenue $79.74 billion tak pahunch sakta hai. Vaccine market mein bhi 8.50% ka CAGR expected hai 2033 tak. Lekin true potential unlock karne ke liye India ko sirf ek great manufacturer se ek innovator banna hoga. Yeh transition Poonawalla bhi chahte hain – deep R&D, agile regulations, aur robust supply chains ko apna strategic pillar banana hoga. Yahi India ke vaccine future ko secure karega.